Skip to main content
Fig. 10 | Journal of Nanobiotechnology

Fig. 10

From: Application of fluorocarbon nanoparticles of 131I-fulvestrant as a targeted radiation drug for endocrine therapy on human breast cancer

Fig. 10

In vivo toxicity test: A Safety assessment of drug: HE staining of major organs. B Changes in body weight of experimental mice in each treatment group during administration. C Impact of different drug treatments on liver function biomarkers in mice: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). D Impact of different drug treatments on renal function biomarkers in mice: blood urea nitrogen (BUN) and creatinine (CRE). E Impact of different drug treatments on hematological parameters in mice: white blood cells (WBC), red blood cells (RBC), platelets (PLT).a:PBS, b:Fulvestrant, c:131I-Fulvestrant, d:131I-fulvestrant-PFP-NPs,e:131I-fulvestrant-PFP-FA-NPs, f:131I-fulvestrant-ALA-PFP-FA-NPs(Scale bar represents 50 μm for all panels, Values are Mean ± S.D., n = 5)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us